Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(20%)

Phase Distribution

Ph phase_1

80%

Ph phase_2

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

4(80.0%)

Phase 2Efficacy & side effects

1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(1)

Detailed Status

Completed4

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 2

Trials by Phase

Phase 14 (80.0%)

Phase 21 (20.0%)

Trials by Status

completed480%

terminated120%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_1

A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)

NCT00102505

completedphase_1

A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas

NCT00080054

completedphase_1

Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors

NCT00080041

terminatedphase_1

Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

NCT00080028

completedphase_2

A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

NCT00096837

Clinical Trials (5)

Showing 5 of 5 trials

NCT00102505Phase 1

A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)

Completed

NCT00080054Phase 1

A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas

Completed

NCT00080041Phase 1

Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors

Completed

NCT00080028Phase 1

Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

Terminated

NCT00096837Phase 2

A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5